Hepatocellular carcinoma shows low response to most conventional chemotherapies; additionally， extrahepatic metastasis from hepatoma is considered refractory to conventional systemic chemotherapy. Target therapy is a promising strategy for advanced hepatoma; however， targeted accumulation and controlled release of therapeutic agents into the metastatic site is still a great challenge. Folic acid (FA) and paclitaxel (PTX) containing composite micelles (FA-M[PTX]) were prepared by coassembling the FA polymer conjugate and PTX polymer conjugate. The main purpose of this study is to investigate the inhibitory efficacy of FA-M(PTX) on the pulmonary metastasis of intravenously injected murine hepatoma 22 (H22) on BALB/c mice models. The lung metastatic burden of H22 were measured and tissues were analyzed by immunohistochemistry and histology (hematoxylin and eosin stain)， followed by survival analysis. The results indicated that FA-M(PTX) prevented pulmonary metastasis of H22， and the efficacy was stronger than pure PTX and simple PTX-conjugated micelles. In particular， the formation of lung metastasis colonies in mice was evidently inhibited， which was paralleled with the downregulated expression of matrix metalloproteinase-2 and matrix metalloproteinase-9. Furthermore， the mice bearing pulmonary metastatic hepatoma in the FA-M(PTX) group gained significantly prolonged survival time when compared with others given equivalent doses of PTX of 30 mg/kg. The enhanced efficacy of FA-M(PTX) is theoretically ascribed to the target effect of FA; moreover， the extensive pulmonary capillary networks may play a role. In conclusion， FA-M(PTX) displayed great potential as a promising antimetastatic agent， and the FA-conjugated micelles is a preferential targeted delivery system when compared to micelles without FA.